The SU2C-SARC032 study demonstrated that pembrolizumab combined with radiotherapy and surgery was well tolerated, with ...

Potential practice-changing therapies in gynecologic cancer include the emergence of carboplatin, paclitaxel, and PD-1 ...

The past 12 months have seen the FDA approvals of enfortumab vedotin plus pembrolizumab for patients with locally advanced or ...

The European Society for Medical Oncology (ESMO) Congress featured findings on overall survival, disparities, and artificial ...

The following is a summary of “A potential inflammatory biomarker for advanced endometrial cancer treated with lenvatinib ...

High levels of immune infiltrates are strongly prognostic for favorable outcomes independently of nodal status in ...

Lenvatinib plus pembrolizumab did not improve PFS or OS over chemotherapy in patients with advanced or recurrent endometrial ...

The Jimmy Carter drug introduced the world to cancer immunotherapy, a treatment that differs from chemotherapy. Carter was ...

The following is a summary of “Neoadjuvant Pembrolizumab in Stage I-III Deficient Mismatch Repair Colon Cancer: A Clinical ...

At the heart of the plan that was hatched was an immunotherapy treatment named Pembrolizumab, which the federal government subsidised under PBS for Mr Hewlett’s particular molecular subtype of ...

Recent advances in immunotherapy have shown promising survival benefits. Here, we present a case of LCC successfully treated with a combination of surgery and pembrolizumab. A 56-year-old male smoker, ...

Background: The addition of durvalumab or pembrolizumab to gemcitabine and cisplatin (GP) has been approved to statistically improve survival outcomes in patients with advanced biliary tract cancer.